Evidence map›Paper›PMID 35575005›Full record

ArticleBJU international2022

Optimized detection of germ cell neoplasia in situ in contralateral biopsy reduces the risk of second testis cancer.

Ewa Rajpert-De Meyts, Niels Jørgensen, Jørgen Holm Petersen, Kristian Almstrup, Lise Aksglaede, Jakob Lauritsen, Mikael Rørth, Gedske Daugaard, Niels E Skakkebaek

Open access · hybridAbstract read
In one paragraph

Article in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Testicular germ cell tumour arising 15 years after radiotherapy with 18 Gy for germ cell neoplasia in situ.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ewa Rajpert-De MeytsDepartment of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen.ORCID 0000-0002-5946-7559
Niels JørgensenDepartment of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen.
Jørgen Holm PetersenDepartment of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Kristian AlmstrupDepartment of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen.
Lise AksglaedeDepartment of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen.
Jakob LauritsenDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Mikael RørthDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Gedske DaugaardDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Niels E SkakkebaekDepartment of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen.
Copenhagen University Hospital · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate whether optimized and standardized diagnostic procedures would improve detection of germ cell neoplasia in situ (GCNIS) in the contralateral testis of patients with testicular germ cell tumour (TGCT) and decrease the rate of metachronous tumours, which in a nationwide Danish study was estimated to be 1.9%. PATIENTS AND

methodsThis was a retrospective analysis of outcomes in 655 patients with TGCT who underwent contralateral biopsies (1996-2007) compared with those in 459 non-biopsied TGCT controls (1984-1988). The biopsies were performed using a standardized procedure with immunohistochemical GCNIS markers and assessed by experienced evaluators. Initial histopathology reports were reviewed, and pathology and survival data were retrieved from national Danish registers. In 604/608 patients diagnosed as GCNIS-negative (four were lost to follow-up), the cumulative incidence of metachronous TGCT was estimated in a competing risk setting using the Grey method. All cases of metachronous TGCT were re-examined using immunohistochemistry.

resultsGerm cell neoplasia in situ was found in 47/655 biopsied patients (7.2%, 95% confidence interval [CI] 5.4-9.5%). During the follow-up period (median 17.3 years) five of the 604 GCNIS-negative patients developed a TGCT. In 1/5 false-negative biopsies, GCNIS was found on histological revision using immunohistochemistry and 2/5 biopsies were inadequate because of too small size. The estimated cumulative incidence rate of second tumour after 20 years of follow-up was 0.95% (95% CI 0.10%-1.8%) compared with 2.9% (95% CI 1.3%-4.4%) among the non-biopsied TGCT patients (P = 0.012). The estimates should be viewed with caution due to the small number of patients with metachronous TGCT.

conclusionsOptimized diagnostic procedures improved the detection rate of GCNIS in patients with TGCT and minimized their risk of developing metachronous bilateral cancer. Urologists should be aware of the importance of careful tissue excision (to avoid mechanical compression) and the need of adequate biopsy size. Performing contralateral biopsies is beneficial for patients' care and should be offered as a part of their management.

Indexed as

Neoplasms, Germ Cell and EmbryonalNeoplasms, Second PrimaryTesticular NeoplasmsBiopsyGerm CellsHumansMaleRetrospective StudiesTestisdiagnosisGCNISgerm cell cancerimmunohistochemistrytesticular biopsy#TesticularCancer#tscsm#uroonc

Identifiers

PMID35575005
PMCPMC9796833
OpenAlexW4280557440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.